MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Adenosine antagonists"

  • 2018 International Congress

    Combined administration of A2A receptor antagonist and 5-HT1A/1B receptor agonist reverses neuroinflammation in the 6-OHDA model of Parkinson’s disease

    A. Pinna, G. Costa, M. Serra, M. Morelli (Monserrato (CA), Italy)

    Objective: To investigate whether in a model of Parkinson's Disease (PD), an early treatment with the serotonin 5-HT1A/1B receptor agonist eltoprazine and the adenosine A2A…
  • 2018 International Congress

    The complementary relationship between zonisamide and istradefylline in treating patients with Parkinson’s disease

    T. Kadowaki, M. Hamaguchi, H. Sakuramoto, T. Shiina, H. Fujita, K. Suzuki, K. Hirata (Mibu, Japan)

    Objective: To investigate patients with Parkinson’s disease (PD) who received zonisamide and istradefylline at the same period. Background: Zonisamide and istradefylline are anti-PD drugs with…
  • 2017 International Congress

    Efficacy of Tozadenant in Animal Models of Non-Motor Symptoms of Parkinson’s Disease

    C. Kostrub, C. Kenney, C. Riemer, E. Prinssen, A. Flohr, J.-L. Moreau (Ardsley, NY, USA)

    Objective: Investigate the potential of tozadenant (TOZ) to alleviate the non-motor symptoms of Parkinson's disease using multiple animal models. Background: TOZ is an oral, selective…
  • 2017 International Congress

    Design and discovery of 1,2,4 triazole derivatives as adenosine A2A receptor antagonist against parkinson’s disease

    A. Verma, V. Kumar, U. Singh (Allahabad, India)

    Objective: In the present study, we intended to develop novel 1,2,4 triazole as potent A(2A)AR antagonists against parkinson’s disease. Background: Parkinson’s disease (PD) is a…
  • 2017 International Congress

    Istradefylline improves motor symptoms in Parkinson’s disease: A meta-analysis

    W. Sako, N. Murakami, K. Motohama, Y. Izumi, R. Kaji (Tokushima, Japan)

    Objective: The aim of this meta-analysis was to provide strong evidence for the main and side effects of istradefylline on patients with Parkinson’s disease. Background:…
  • 2017 International Congress

    Istradefylline improves not only motor symptoms but also sleep disturbance, daytime sleepiness, and QOL of Parkinson’s disease patients.

    K. Ohta, Y. Kujuro, T. Osada (Tokyo, Japan)

    Objective:  This study analyzed the clinical effectiveness of istradefylline in terms of sleep disturbance in Parkinson’s disease (PD) patients. Background: A selective adenosine A2A receptor…
  • 2017 International Congress

    Caffeine as a Treatment for Parkinson’s Disease: A Randomized Controlled Trial (CafePD)

    R. Postuma, J. Anang, A. Pelletier, M. Moscovich, D. Grimes, A. Borys, S. Furtado, R. Munhoz, S. Cresswell, A. Moro, D. Hobson, L. Joseph, A. Lang (Montreal, QC, Canada)

    Objective: To assess the effects of caffeine on patients with Parkinson's disease. Background: Multiple studies have linked use of caffeine, an adenosine antagonist, to a…
  • 2017 International Congress

    Istradefylline and Preladenant as adjuvant therapies for Patients with Parkinson’s disease

    A. Negida, Z. Hassan, H. Ahmed, O. Hassan, A. Elsherbiny, S. Azzam, O. Osama, Y. Ibrahim (Zagazig, El-Sharkia, Egypt)

    Objective: The aim of this meta-analysis is to synthesize evidence about the efficacy of the adenosine receptor antagonists (Istradefylline and Preladenant) for patients with Parkinson’s…
  • 2016 International Congress

    Anxiolytic-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) in rodent models of anxiety

    K. Yamada, M. Kobayashi, J. Kase, A. Mori, P. Jenner, T. Kanda (Shizuoka, Japan)

    Objective: The aim of this study was to assess the anxiolytic effects of istradefylline (KW-6002), an adenosine A2A receptor antagonist, in naive and anxiety-prone animals…
  • 2016 International Congress

    Differences between responders and non-responders of Istradefylline for the wearing off in Parkinson’s disease

    A. Yoritaka, H. Mori, N. Hattori (Saitoma, Japan)

    Objective: Istradefylline is a selective antagonist of adenosine A2A receptor and was approved first in Japan for Parkinson's disease (PD) patients with by symptoms of…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley